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Introduction
The main pathological syndrome of coronavirus disease 19 
(COVID-19) is an severe acute respiratory syndrome co-
ronavirus 2 (SARS-CoV-2). Recently, however, many rese-
archers have drawn attention to a significant coagulation 
imbalance in COVID-19 patients, confirmed by laboratory 
findings [1–5] as well as postmortem data [6]. The num-
ber of studies on coagulopathy in COVID-19 patients with 
SARS-CoV-2 is limited. Also, there are currently no studies 
that would analyze von Willebrand factor (vWF) activity in 
these patients at critical stage. Consequently, the objective 
of this study was to determine the changes in coagulation 
parameters that are specific for COVID-19 patients.
Materials and methods
We analyzed the coagulation status in 16 confirmed COVID-19 
patients who received treatment at the intensive care units 
(ICUs) at the Mogilev Hospital No.1 and Mogilev Regional 
Clinical Hospital, Republic of Belarus, in the period from 
March 1 to May 20, 2020. The COVID-19 diagnosis was 
confirmed by reverse transcription-polymerase chain reaction 
(RT-PCR) and chest computed tomography (CT) scan where 
the specific manifestations (i.e. ground-glass opacity and con-
solidation) were observed. All patients were admitted to the 
ICU with moderate to severe respiratory distress syndrome 
in accordance with the Berlin definition and classification.
Of the 16 patients enrolled, six (37.5%) were male 
and 10 (62.5%) were female; the median (interquarti-
le range) age was 59.0 (51.5–70) years, the weight was 
91.0 (78–108) kg, the height was 168.0 (167–171) cm, 
and the body mass index was 31.2 (27.1–37.9) kg/m2. 
12 patients received respiratory support, and another four 
patients received high-flow oxygen therapy. Of the 16 pa-
tients enrolled, 10 (62.5%) patients were transferred from 
the ICU for follow-up care, and six (37.5%) patients died.
At the time of blood sampling for the study, all patients 
received anticoagulant therapy: eight patients received eno-
xaparin sodium 4,000 IU anti-Xa/day, two patients received 
sodium dalteparin 10,000 IU anti-Xa/day, four patients re-
ceived sodium dalteparin 20,000 IU anti-Xa/day, and two 
patients received unfractionated heparin 20,000 units/day.
The coagulation status was determined once on the first 
day of ICU admission. Blood samples were collected using 
vacuum blood collection systems. To perform the study, an 
automatic haemostasis analyzer ACL 10000 (Instrumenta-
tion Laboratory, MA, USA) was used. The following assays 
were performed: activated partial thromboplastin time 
(APTT), prothrombin time (PT), international normalized 
ratio (INR), prothrombin complex activity (PCA), fibrinogen, 
plasminogen, antithrombin III, D-dimers, and vWF activity.
The data was presented as median and interquartile 
range (median (25th–75th quartiles). Statistical analysis was 
performed using Statistica 7.0 (StatSoft, Inc., OK, USA).
Results and discussion
The data obtained are shown in (Table I). The values were 
compared with the average reference values.
In the study patients, the following results were co-
agulation parameters: normal to moderately increased 
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APTT values; normal prothrombin time values, normal 
INR values; normal prothrombin complex activity; normal 
plasminogen level; normal antithrombin III level; increa-
sed fibrinogen and D-dimer levels; significantly increa-
sed vWF activity.
Increase in D-dimer and fibrinogen levels in CO-
VID-19 indicates the hypercoagulation among these pa-
tients. The vWF plays an essential role in primary hae-
mostasis by ensuring platelet adhesion to the damaged 
vascular wall and their further aggregation as well as by 
binding to factor VIII and stabilising it [7, 8]. An increase 
in the activity of vWF to such extreme values indicates the 
important role of endothelial damage and its high involve-
ment in the pathological process that occurs in the condi-
tions of a systemic inflammatory response caused by CO-
VID-19 infection. In addition, an increase in the activity of 
vWF to extreme values is evidence of extreme instability 
of hemostasis with all its pathophysiological and clinical 
consequences.
Undoubtedly, this issue requires a more detailed stu-
dy and careful analysis to ensure the correct interpreta-
tion of this parameter and further use of the vWF acti-
vity in clinical practice for diagnosis and treatment of 
COVID-19 patients. vWF activity may be used to develop 
new approaches to assess the severity of hemostasis di-
sorders while COVID-19. It is also likely that the vWF may 
be a target for monoclonal antibody therapy or protease 
specific therapy.
Conclusion
Increased fibrinogen and D-dimer levels indicate that 
COVID-19 patients are in a state of hypercoagulation. In 
all patients, also a significant increase in vWF activity was 
observed. The increase in vWF activity reflects the of vascu-
lar endothelial damage in COVID-19 and may be one of the 
important causes of coagulation disorder in these patients.
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Table I. Haemostasis and von Willebrand factor (vWF) activity in study patients
Parameter Reference range: 
lower-upper limits
n Observations






PT ratio [s] 11.9–16.1 16 15.7 (14.7–16.5)
13.4–21.8
0 (0) 5 (31.3)
APTT ratio [s] 24.6–35 16 35.2 (30–44.25)
26.8–175
0 (0) 8 (50)
INR 0.85–1.15 16 1.14 (1.06–1.21)
0.95–1.68
0 (0) 6 (37.5)
PCA [%] 70–130 16 88.5 (81.8–99.7)
50.6–119.0
1 (6.3) 0 (0)
Fibrinogen [g/L] 2.0–4.0 16 4.98 (3.84–5.74)
3.13–7.41
0 (0) 12 (75.0)
Plasminogen [%] 81.4–141 12 96.2 (79.4–110.0)
53.4–132
3 (25.0) 0 (0)
Antithrombin III [%] 83–128 16 90.3 (69.3–105.5)
59.1–132
6 (37.5) 2 (12.5)
D-dimer [µg/mL] 0–0.26 13 0.45 (0.31–0.56)
0.26–3.38
– 12 (92.3)
vWF [%] 38–169 16 448 (335–513)
223.2-889
0 (0) 16 (100)
PT ratio — prothrombin time ratio; APTT ratio — activated partial thromboplastin ratio; INR — international normalized ratio; PCA — prothrombin complex activity
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